RT Journal Article
SR Electronic
T1 Correlation of Tumor Location to Clinical Outcomes in Colorectal Cancer: A Single-institution Retrospective Analysis
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4917
OP 4924
DO 10.21873/anticanres.13679
VO 39
IS 9
A1 CARLO SIGNORELLI
A1 MARIO GIOVANNI CHILELLI
A1 ISABELLA SPERDUTI
A1 SILVANA GIACINTI
A1 PIETRO MARIA AMODIO
A1 RAFFAELE MACARONE PALMIERI
A1 TERESA VALENTINA RANALLI
A1 VITO VINCENZO GOMES
A1 MARIA ELENA ROSETTO
A1 FABRIZIO NELLI
A1 ENZO MARIA RUGGERI
YR 2019
UL http://ar.iiarjournals.org/content/39/9/4917.abstract
AB Background/Aim: Recent data highlighted that location of metastatic colorectal cancer (mCRC) may have a prognostic impact and also a predictive value of the outcomes of first-line therapy. Materials and Methods: The records of mCRC patients who underwent first-line therapy from 2011 to April 2018 at our Institute were retrospectively reviewed. Progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) according to the primary tumor location were investigated. Results: Overall, 130 patients were eligible. Two-year OS was 82.9% in left-sided colon cancers (LCC) and 67.5% in right-sided (RCC) (p=0.32). One-year mPFS was statistically longer in LCC (46.8% vs. 24.2%, p=0.0005). mPFS was longer in LCC treated with anti-VEGF vs. anti-EGFR (p=0.06). ORR was 51.1% in LCC, 25% in RCC (p=0.008). Overall, 11 complete responses all in LCC were observed (p=0.03). Conclusion: Tumor location has a prognostic impact and might influence the outcomes of mCRC patients.